dual orexin receptor GPCR antagonist

Ph. III efficacy for insomnia, oral 25-50 mg

from optimization of prior clinical candidate

ChemMedChem., Oct. 28, 2020

Idorsia Pharmaceuticals, Allschwil, CH

Structure of Daridorexant, an oral dual-orexin receptor antagonist (DORA)

Idorsia clinical dual orexin receptor GPCR antagonist

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: